REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, May 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

GlobeNewsWire • 17 hours ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • May 15, 2026

Replimune: Perhaps The FDA Shakeup Will Get A Mulligan For RP1

Replimune Group, Inc.'s RP1 has failed at the FDA twice, but Makary's resignation keeps a resubmission possible. REPL's cash runway stands at under a year; workforce cuts and RP1 discontinuation are being considered. I maintain a cautious Buy on the ability for REPL to court surprising, bold turnarounds. I don't think this story is over.

Seeking Alpha • May 13, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPL

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

GlobeNewsWire • May 12, 2026

FDA Commissioner Makary defends agency's decision on Replimune's drug

U.S. Food and Drug ​Administration Commissioner Dr. ‌Marty Makary on Tuesday defended ​the agency's ​decision to not approve ⁠Replimune's drug ​for advanced ​skin cancer.

Reuters • May 5, 2026

What's Going On With Replimune Stock On Tuesday?

U.S. Food and Drug Administration (FDA) Commissioner Marty Makary defended his leadership in a CNBC interview aired Tuesday, growing criticism with concerns centering on drug approval decisions and internal leadership disputes that have sparked political and public backlash.

Benzinga • May 5, 2026

US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

Health Secretary Robert F. Kennedy Jr. told ​a Senate hearing on Wednesday that he had nothing to do with the U.S. FDA's ‌decision to not approve Replimune's drug for advanced skin cancer, saying it was in the hands of the agency's Commissioner Dr. Marty Makary.

Reuters • Apr 22, 2026

Replimune melanoma therapy rejected by FDA, shares plunge

Replimune Group (NASDAQ:REPL) shares fell roughly 63% following the company's disclosure that it received a Complete Response Letter (CRL) from the US Food and Drug Administration, effectively blocking the approval of its lead melanoma therapy RP1 in combination with nivolumab. The decision represents a significant setback for the biotechnology company, which had been seeking approval based on data from its IGNYTE clinical program in patients with advanced melanoma who had progressed on prior anti-PD-1 therapy.

Proactive Investors • Apr 13, 2026

Replimune co-founder calls FDA rejection of melanoma drug ‘unfair'

Philip Astley-Sparke, executive chairman and co-founder at Replimune, joins ‘Squawk on the Street' to discuss the company's next steps after the FDA denied its melanoma drug.

CNBC Television • Apr 13, 2026

FDA Rejection Sparks Questions On Replimune Drug Approval Path

Replimune Group Inc. (NASDAQ: REPL) on Friday received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration for its Biologics License Application.

Benzinga • Apr 13, 2026